» Articles » PMID: 12790888

Intrastriatal Methylmalonic Acid Administration Induces Convulsions and TBARS Production, and Alters Na+,K+-ATPase Activity in the Rat Striatum and Cerebral Cortex

Overview
Journal Epilepsia
Specialty Neurology
Date 2003 Jun 7
PMID 12790888
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Methylmalonic acid (MMA) inhibits succinate dehydrogenase (SDH) and beta-hydroxybutyrate dehydrogenase activity in vitro. Acute intrastriatal administration of MMA induces convulsions through glutamatergic mechanisms probably involving primary adenosine triphosphate (ATP) depletion and free radical generation. In this study we investigated whether the intrastriatal administration of MMA causes lipoperoxidation and alteration in Na+, K+-ATPase activity ex vivo and characterized the electrographic changes elicited by the intrastriatal administration of this organic acid.

Methods: MMA-induced lipoperoxidation, alterations in Na+, K+-ATPase activity and electrographic changes were measured by measuring total thiobarbituric acid-reacting substances and inorganic phosphate release by spectrophotometry, and by depth electrode recording, respectively.

Results: We demonstrated that intrastriatal MMA (6 mmol) injection causes convulsive behavior and electrographically recorded convulsions that last approximately 2 h. Concomitant with the increase of thiobarbituric acid-reacting substances (TBARS) content, we observed a significant inhibition of Na+,K+-ATPase activity in the striatum, and activation of Na+,K+-ATPase activity in the ipsilateral cerebral cortex. Intrastriatal MMA injection increased the content of TBARS in the striatum measured 30 min (32.4 +/- 12.0%, compared with the noninjected contralateral striatum) and 3 h (39.7 +/- 5.1%, compared with the noninjected contralateral striatum) after MMA injection. TBARS content of the ipsilateral cerebral cortex increased after MMA injection at 30 min (42.1 +/- 6.0%) and 3 h (40.4 +/- 20.2%), and Na+,K+-ATPase activity in the ipsilateral cerebral cortex increased during ictal activity (113.8 +/- 18%) and returned to basal levels as electrographic convulsions vanished in the cortex. Interestingly, intrastriatal MMA administration induced a persistent decrease in Na+,K+-ATPase activity only in the injected striatum (44.9 +/- 8.1% at 30 min and 68.7 +/- 9.4 at 3 h).

Conclusions: These data suggest that MMA induces lipoperoxidation associated with Na+,K+-ATPase inhibition or activation, depending on the cerebral structure analyzed. It is suggested that Na+,K+-ATPase inhibition may play a primary role in generating MMA-induced convulsions.

Citing Articles

Neuroprotective effects of L-carnitine towards oxidative stress and inflammatory processes: a review of its importance as a therapeutic drug in some disorders.

Guerreiro G, Deon M, Becker G, Dos Reis B, Wajner M, Vargas C Metab Brain Dis. 2025; 40(2):127.

PMID: 39954226 DOI: 10.1007/s11011-025-01545-6.


Neurodegenerative biomarkers and inflammation in patients with propionic and methylmalonic acidemias: effect of L-carnitine treatment.

Dos Reis B, Becker G, Marchetti D, Coelho D, Sitta A, Wajner M Metab Brain Dis. 2024; 40(1):6.

PMID: 39549096 DOI: 10.1007/s11011-024-01475-9.


Increased serum methylmalonic acid levels were associated with the presence of cognitive dysfunction in older chronic kidney disease patients with albuminuria.

Zhang J, Wu L, Wang S, Pan Y, Zhang A BMC Geriatr. 2024; 24(1):159.

PMID: 38360610 PMC: 10870521. DOI: 10.1186/s12877-024-04759-y.


The Regulation and Characterization of Mitochondrial-Derived Methylmalonic Acid in Mitochondrial Dysfunction and Oxidative Stress: From Basic Research to Clinical Practice.

Liu Y, Wang S, Zhang X, Cai H, Liu J, Fang S Oxid Med Cell Longev. 2022; 2022:7043883.

PMID: 35656023 PMC: 9155905. DOI: 10.1155/2022/7043883.


Systemic delivery of selective EP1 and EP3 receptor antagonists attenuates pentylenetetrazole-induced seizures in mice.

Reschke C, Poersch A, Masson C, Jesse A, Marafiga J, Lenz Q Int J Physiol Pathophysiol Pharmacol. 2018; 10(1):47-59.

PMID: 29593850 PMC: 5871629.